Skip to Main Content

Sierra Oncology is having a very good year.

On Wednesday, the small U.S. drugmaker said it would be acquired by British pharma giant GlaxosmithKline for $1.9 billion. The deal was struck three months after Sierra’s lead drug, a treatment for the blood cancer myelofibrosis, succeeded in a late-stage clinical trial.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment